University of New South Wales, Faculty of Medicine, Kensington, Australia.
Save Sight Institute, Sydney Eye Hospital, Sydney Medical School, University of Sydney, Sydney, Australia.
Autoimmun Rev. 2017 Mar;16(3):213-222. doi: 10.1016/j.autrev.2017.01.003. Epub 2017 Jan 27.
To outline recommendations from an expert committee on the assessment and investigation of patients with severe inflammatory eye disease commencing immunosuppressive and/or biologic therapy.
The approach to assessment is based on the clinical experience of an expert committee and a review of the literature with regard to corticosteroids, immunosuppressive drug and biologic therapy and other adjunct therapy in the management of patients with severe sight-threatening inflammatory eye disease.
We recommend a careful assessment and consultative approach by ophthalmologists or physicians experienced in the use of immunosuppressive agents for all patients commencing immunosuppressive and/or biologic therapy for sight threatening inflammatory eye disease with the aim of preventing infection, cardiovascular, metabolic and bone disease and reducing iatrogenic side effects.
概述专家委员会关于开始免疫抑制和/或生物治疗的严重炎症性眼病患者评估和检查的建议。
评估方法基于专家委员会的临床经验以及对皮质类固醇、免疫抑制剂和生物治疗以及严重威胁视力的炎症性眼病管理中的其他辅助治疗的文献回顾。
我们建议所有开始因严重威胁视力的炎症性眼病而接受免疫抑制和/或生物治疗的患者，由经验丰富的眼科医生或免疫抑制剂使用者进行仔细评估和咨询，目的是预防感染、心血管、代谢和骨骼疾病，并减少医源性副作用。
